company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,49457000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,49457000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,49457000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5664000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16815000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22479000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,26978000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,25000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,76000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27029000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26978000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51974000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.52
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52511000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.51
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q2,2010-04-01,2010-06-30,2011-08-02 08:00:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.52
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,72282000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,72282000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,72282000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5530000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16394000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21924000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,50358000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,90000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-50433000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-50358000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52127000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.97
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52769000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.96
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2010.0,Q3,2010-07-01,2010-09-30,2011-11-01 08:01:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.97
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5754000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15106000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20860000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20860000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,90000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,20781000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,20860000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52275000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52275000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q1,2011-01-01,2011-03-31,2012-05-01 08:00:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,395000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,395000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,395000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4843000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17109000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21952000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21557000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,90000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,21474000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,21557000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58272000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.37
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58272000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.37
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q2,2011-04-01,2011-06-30,2012-08-07 08:00:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.37
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4355000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4355000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4355000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5080000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17316000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22396000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18041000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,114000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,17931000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18041000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71226000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71226000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q3,2011-07-01,2011-09-30,2012-11-06 08:00:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6091000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19819000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25910000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25910000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,126000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-60186000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-60063000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-85973000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-85973000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-85973000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-85973000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,63329000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.62
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,63329000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.62
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,63329000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.34
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,750000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,750000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,750000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6156000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17904000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24060000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23310000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,136000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,23174000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,23310000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71422000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q1,2012-01-01,2012-03-31,2013-05-07 12:55:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.32
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1500000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1500000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1500000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5458000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20924000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26382000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24882000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,144000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,144000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71458000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q2,2012-04-01,2012-06-30,2013-08-06 12:44:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.35
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5383000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20186000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25569000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25569000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,113000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,25456000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25569000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71636000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71636000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.36
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q3,2012-07-01,2012-09-30,2012-11-06 08:00:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5852000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19764000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25616000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25616000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,144000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,50210000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,50354000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,24738000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,74967000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.96
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,74967000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.96
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5395000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20315000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25710000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25710000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,136000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,25574000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25710000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,87141000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q1,2013-01-01,2013-03-31,2013-05-07 12:55:50+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4892000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19393000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24285000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22885000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,117000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,117000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22768000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22768000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22768000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22768000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,87147000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q2,2013-04-01,2013-06-30,2013-08-06 12:44:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4677000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17574000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1679000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23930000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23930000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,106000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,106000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23824000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23824000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23824000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23824000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,88200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.27
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,88200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.27
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,87430000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q3,2013-07-01,2013-09-30,2013-11-05 08:01:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.27
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-1400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-1400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-1400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,-14964000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,-57282000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-1679000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-73925000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,72525000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-359000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-25574000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-25933000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,46592000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,46592000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,46592000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,46592000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.27
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.27
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.82
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20383000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20383000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20383000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20908000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,63446000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,5770000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-88000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,90036000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-69741000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,437000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,437000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-69304000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-69304000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-69304000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-69304000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,94900000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.73
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,94900000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.73
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,94387000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.73
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,900000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,900000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,900000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7947000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10808000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18755000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17855000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,195000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,195000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17660000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17660000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17660000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17660000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,126100000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,126100000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,124628000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 16:06:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3584000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3584000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3584000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,29884000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35461000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,65345000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-61761000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,697000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,697000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-61064000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-61064000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-61064000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-61064000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,127000000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.48
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,127000000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.48
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,126324000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.48
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13492000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11242000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24734000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24734000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,349000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,349000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24385000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24385000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24385000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24385000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,143400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,143400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,147114000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q1,2018-01-01,2018-03-31,2019-05-07 16:06:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1787000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1787000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,30000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,30000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1757000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17071000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10797000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27868000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26111000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,554000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,554000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-25557000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25557000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25557000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-25557000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,159700000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,159700000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,161577000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:09:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4865000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4865000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,69000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,69000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4796000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18069000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11097000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29166000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24370000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,604000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,604000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23766000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23766000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23766000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23766000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,169800000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,169800000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,166464000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q3,2018-07-01,2018-09-30,2018-11-06 16:06:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,37857000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,37857000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,188000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,188000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37669000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,21370000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13767000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35137000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2532000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,696000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,696000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3228000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3228000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3228000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3228000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,160200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.03
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,160200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.03
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,160529000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.03
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12624000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12624000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,107000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,107000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12517000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,19946000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10949000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30895000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18378000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,780000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,780000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17598000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17598000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17598000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17598000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,167173000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,167173000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,167173000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q1,2019-01-01,2019-03-31,2020-05-05 16:06:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10407000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10407000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,311000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,311000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10096000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18209000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13226000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31435000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21339000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,733000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,733000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20606000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20606000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20606000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20606000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,171700000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,171700000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,167191000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:09:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20857000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20857000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,310000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,310000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20547000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18121000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14463000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32584000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12037000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,555000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,547000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11490000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11490000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11490000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11490000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,164100000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,164100000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,167609000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 16:15:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,178000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,178000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15222000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18312000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14247000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32559000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17337000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,327000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,464000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,137000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,167200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,167200000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,167400000.0
Rigel Pharmaceuticals Inc,RIGL,,0001034842,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
